Clinical trial
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients…
NCT00087217 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00087217 |
|---|---|
| Title | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor |
| Official title | Phase I Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination With Paclitaxel in Advanced Solid Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, paclitaxel, laboratory biomarker analysis, pharmacological study |
| Enrollment | 35 |
| Start date | May 1, 2004 |
| Primary completion | Jun 1, 2008 |
| First posted | Jul 12, 2004 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: